Bisacodyl

contact (stimulant) laxative, diphenylmethane (A06AB); not an anthraquinone

Also sold as Dulcolax, Correctol, Feen-a-Mint, Carter's Little Pills.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Bisacodyl has no classical depletion machinery of the enzyme-induction, chelation or transporter-competition kind. It is a prodrug hydrolyzed by intestinal brush-border enzymes and colonic bacteria to the active metabolite BHPM [4]; the kit label states that the oral pharmacokinetics of the tablet "has not been adequately characterized" [4], and the OTC labels carry no pharmacokinetic, interaction or nutrient section [1][2][3]. Absorption is described as minimal [6][7], yet a study with an 8-woman bisacodyl arm measured total BHPM (mostly glucuronide) in plasma, with a geometric-mean Cmax near 61 to 65 ng/mL on 10 mg daily and about 12% of the dose recovered in urine as BHPM [7], so "no systemic exposure" is not what the measurements show. No CYP450 data were retrieved: unknown, not absent. Nothing reaches red or orange, because no Tier A source with bisacodyl in the cohort shows a measured nutrient deficit. The potassium, plasma protein, fluid and sodium, and calcium signals are all drug effects of overuse: case reports describe hypokalemia with doses of 300 to 500 mg/day, which is 30 to 50 times the 10 mg WHO defined daily dose [5][18], and a 1968 case of bisacodyl-linked plasma protein loss into the gut [14]. Those entries run as fecal-loss disturbances in a misuse context and are not dietary shortfalls. A 600-subject bowel-preparation trial that included a bisacodyl arm found no serum potassium difference among arms [20].

contact (stimulant) laxative, diphenylmethane (A06AB); not an anthraquinone · ATC A06AB02 · also sold as Dulcolax and Correctol and Feen-a-Mint and Carter's Little Pills and PMS-Bisacodyl; many OTC generics; component of bowel-preparation kits · reviewed 2026-10-04. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Bisacodyl in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe: Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Potassium: loss with chronic or high-dose misuse, case level only; direction depletion by fecal loss

Yellow — Low

Evidence in: Tier B (context: misuse)

Case reports describe low serum potassium in people misusing bisacodyl at many times the labeled dose, usually with eating-disorder or concealed-laxative context. No controlled study of bisacodyl at labeled doses showed a potassium change. This is a drug effect of overuse, not a dietary shortfall.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. Yellow, Tier B (context: misuse)

Limits on what this shows

Key null findings: Gerard 2012: investigator-blinded RCT, 600 subjects (200 per arm) comparing NuLYTELY, Gatorade/PEG with placebo and Gatorade/PEG with bisacodyl 10 mg; serum potassium showed no significant differences among arms, and creatinine did not differ either. The comparison is a single bowel-preparation exposure, the electrolyte content of the three solutions differs, and magnesium was not measured, so it neither tests chronic use nor isolates bisacodyl cleanly [20]. Whorwell 2024 reports that no bisacodyl-specific hypokalemia study was identified in its review [11]. The 2011 Clinical Gastroenterology and Hepatology trial 'Oral bisacodyl is effective and well-tolerated in patients with chronic constipation' could not be opened (403), so any lab data it holds are unknown.
At-risk subgroups: People with chronic high-dose or concealed use; people with eating disorders who use laxatives to purge (the two Kato cases); people who also vomit or use diuretics (not studied here).

Regulatory status

The three OTC labels retrieved carry no potassium statement; they limit use to 1 week [1][3]. The bowel-preparation kit label warns of serious fluid and serum chemistry abnormalities and says seizure cases were associated with hyponatremia, hypokalemia, hypocalcemia and hypomagnesemia; the kit is a PEG electrolyte solution plus one 5 mg bisacodyl tablet and the label does not separate the components, so that warning is a drug-effect statement for the kit and not for bisacodyl alone [4]. The professional monograph lists hypokalemia among effects of prolonged use [6].

Population evidence

Tier B. Kato 2004: two young women with anorexia nervosa and laxative abuse, bisacodyl 300 to 500 mg/day, ammonium acid urate stones, markedly reduced urine volume, hyponatremia and hypokalemia (abstract via OpenAlex) [18]. Sidler 2019: a 45-year-old woman with potassium frequently below 2.5 mmol/L (2.9 on reevaluation), bicarbonate 16 mmol/L and chloride 111 mmol/L, laxative abuse found when potassium citrate failed; testing was positive for emodin, bisacodyl and rhein, so bisacodyl is one of three agents and is not isolated [17]. A 2021 Reactions Weekly item titled 'Bisacodyl abuse/overdose: hypokalaemia, malnutrition and chronic hepatitis: case report' was seen at title and subtitle level only, with details behind a paywall [19]. Kacere 1993 describes surreptitious bisacodyl use with secretory-pattern watery diarrhea; the abstract reports no potassium value [15]. Ritsema and Eilers 1994 ('Potassium supplements prevent serious hypokalaemia in colon cleansing') lists bisacodyl in its index terms but no abstract could be read, so it is not used [34].

Class extrapolation (Tier C)

CLASS EXTRAPOLATION, not bisacodyl: Nata 2021, an RCT of senna glycoside in 73 hemodialysis patients (37 vs 36, 8 weeks), lowered pre-dialysis serum potassium by 0.32 mEq/L against 0.02 with control (abstract via OpenAlex) [28]. Cohort test: senna glycoside only; bisacodyl was not in the cohort. Senna is an anthraquinone and bisacodyl a diphenylmethane, so the shared ATC subgroup (A06AB) is the only link. Used only to show that potassium is a measurable endpoint for contact laxatives in dialysis patients, and capped at yellow.

Mechanism

Named and plausible: BHPM drives prostaglandin-dependent chloride secretion and lowers aquaporin-3 so water is retained in the lumen [9][10]; a manufacturer-hosted summary describes luminal BHPM as driving potassium secretion [8]. Excess stool volume then carries potassium out. A renal tubular route is not described.

Counter-evidence held on record

Counter-evidence on record Confounding by indication and co-exposure is presumed (Hard Rule 6): the cases involve anorexia nervosa, malnutrition, vomiting, mixed agents and doses 30 to 50 times the 10 mg defined daily dose [5][18]. The kit-label warning belongs mainly to the large-volume PEG solution. No study of bisacodyl at labeled doses with potassium as the outcome was retrieved, which is why this is not graded higher. Framing caution This is potassium lost through the gut with overuse, not a diet shortfall. It is not an instruction to increase potassium intake, and potassium replacement belongs with a clinician who has a measured level. No dose is given anywhere in this dossier. Persistent diarrhea, palpitations or muscle weakness warrants clinician review.

Plasma protein loss into the gut: one bisacodyl case from 1968; outcome of misuse, not dietary protein

Yellow — Low

Evidence in: Tier B (context: misuse)

A 1968 report of two factitious-diarrhea patients, one on phenolphthalein and one on bisacodyl, found low serum albumin and radiolabeled-albumin evidence of excess protein loss into the gut that mostly reversed on stopping the laxative.

Full detail and limits

Limits on what this shows

Key null findings: In Kacere 1993, two surreptitious-bisacodyl cases had 24-hour stool volumes above 2 L but fecal fat under 3 g, a stool osmotic gap below 30 mEq/L and fecal leukocytes; one showed nonspecific inflammatory colonic changes on biopsy. Albumin was not reported in the abstract, but the low fecal fat argues against fat malabsorption in those cases [15]. Whorwell 2024 states no bisacodyl-specific protein-losing enteropathy study was identified [11].
At-risk subgroups: People with chronic high-dose or concealed use and prolonged watery diarrhea.

Regulatory status

No protein statement on the OTC labels or the kit label [1][2][3][4]. The monograph states that extended misuse can result in cathartic colon with atony and dilation and in protein-losing enteropathy and steatorrhea, with no primary citation visible in the retrieved text [6].

Population evidence

Tier B case report. Heizer, Warshaw, Waldmann and Laster, Ann Intern Med 1968: two patients with factitious diarrhea, one with excessive phenolphthalein use and one with bisacodyl; both had hypoalbuminemia and mild malabsorption; 51Cr-albumin studies showed excessive plasma protein loss into the gastrointestinal tract; most abnormalities reversed on stopping the cathartic and one patient had persistent edema needing sodium restriction. Abstract reconstructed from an OpenAlex record; the dose, which patient had which finding, and the albumin values were not retrieved [14].

Mechanism

Not stated in the retrieved abstract. The monograph attributes it to extended misuse [6]. Local mucosal injury is documented separately [11][16] but no study links it to protein loss, so no mechanism is claimed.

Counter-evidence held on record

Counter-evidence on record One bisacodyl patient in a pair, abstract-level, 1968 methods. Hypoalbuminemia and edema here are outcomes of gut protein loss and are not a measured dietary protein deficiency (Hard Rule 2). Confounding by concurrent illness cannot be excluded from the abstract. Framing caution This is protein lost from the body through the gut in a misuse context. It is not a reason to eat more protein or take protein supplements, and no dose is given. Swelling or persistent diarrhea warrants clinician review.

Fluid, sodium and acid-base disturbance with misuse (context flag)

Yellow — Low

Evidence in: Tier B (context: misuse)

Misuse case reports describe low sodium, low urine volume and metabolic acidosis; the monograph lists dehydration and acid-base changes with prolonged use. No study measured sodium or acid-base status in bisacodyl users at labeled doses.

Full detail and limits

Limits on what this shows

Key null findings: No sodium or bicarbonate result from a bisacodyl-only controlled study was retrieved. The Gerard sodium difference was not associated with symptoms [20].
At-risk subgroups: People with persistent diarrhea from high-dose or prolonged use; concealed users; older adults.

Regulatory status

OTC labels: stop use for rectal bleeding or no bowel movement; do not use for more than 1 week [1][3]. The kit label warns that fluid and electrolyte disturbances can lead to arrhythmias, seizures and renal impairment, for the PEG plus bisacodyl kit as a whole [4].

Population evidence

Reference text: the monograph lists persistent diarrhea, dehydration, hypokalemia, hypocalcemia and metabolic acidosis or alkalosis with prolonged use [6]. Case level, Tier B: Kato 2004 (hyponatremia and markedly reduced urine volume, bisacodyl 300 to 500 mg/day, anorexia nervosa) [18]; Sidler 2019 (bicarbonate 16 mmol/L with chloride 111 mmol/L, a picture that mimicked distal renal tubular acidosis; agents emodin, bisacodyl and rhein) [17]. Trial level: in Gerard 2012 the two Gatorade/PEG arms had slightly lower serum sodium than NuLYTELY (P below 0.0007), described as small and without clinical symptoms; that comparison is driven by the PEG solutions and does not isolate bisacodyl [20].

Mechanism

The intended secretory action carried to excess (Hard Rule 2): chloride and water secretion with reduced water reabsorption [9][10] produce fluid and bicarbonate loss when diarrhea persists.

Counter-evidence held on record

Counter-evidence on record Confounding by co-use of other laxatives, diuretics, vomiting and poor intake is not separated in any retrieved source (Hard Rule 6). The monograph list is generic stimulant-laxative wording whose bisacodyl specificity is unverified. Framing caution This is a fluid and electrolyte loss disturbance tied to overuse, not a dietary shortfall. It does not mean that sodium, bicarbonate or fluids should be added without a clinician. Persistent diarrhea warrants clinician review.

Calcium: reference-text caution and circulating claim, no measurement isolating bisacodyl

Yellow — Low

Evidence in: Tier B

The monograph and the bowel-preparation kit label list hypocalcemia among electrolyte disturbances, and three consumer documents claim bisacodyl lowers calcium. No study measured calcium in a bisacodyl-only cohort.

Full detail and limits

Limits on what this shows

Key null findings: No calcium, PTH or companion-marker measurement in a bisacodyl-only cohort was found, so no refutation test (Hard Rule 3) is available. Hypocalcemia, where reported, is a disturbance outcome and not filed as a calcium deficiency (Hard Rule 2).
At-risk subgroups: People with persistent diarrhea from prolonged use.

Regulatory status

No calcium effect statement on the OTC labels. The 5 mg enteric-coated tablet lists calcium carbonate among its inactive ingredients, a content statement and not a depletion effect [3]. The kit label lists hypocalcemia among abnormalities associated with seizures [4].

Population evidence

Reference text only for bisacodyl: the monograph lists hypocalcemia among electrolyte disturbances with prolonged use [6]. Trial context: in Gerard 2012 serum calcium was higher in the Gatorade/PEG arms than with NuLYTELY (P below 0.0004); the arms differ in PEG solution, and the direction is opposite to depletion, so it supports nothing for bisacodyl [20]. Claim origins, all Tier D with no citation: InVite Health chart and podcast, and the Riordan Clinic handout list 'Calcium, Potassium' for laxatives with bisacodyl [29][30][31].

Mechanism

No calcium-specific mechanism (for example a PTH-axis effect) is described in any retrieved source; the only route is generic fluid and electrolyte loss with overuse.

Counter-evidence held on record

Counter-evidence on record The monograph wording is generic and its primary citations were not visible. The three consumer sources are one repeated claim and not independent confirmation (see Overlap map). Framing caution This is a disturbance flag for overuse. It is not a reason to take calcium, and no dose is given.

Colonic mucosal injury: drug tissue effect, not a nutrient

Yellow — Low

Evidence in: Tier B (outcome entry)

Bisacodyl causes reversible surface epithelial changes in rodent and human colon at high or supratherapeutic exposure, and a case report describes rectal ulceration after a short oral course. These are drug tissue effects and not nutrient findings.

Full detail and limits

Limits on what this shows

Key null findings: Bisacodyl alone did not induce aberrant crypt foci or tumors in rats [13]. Nothing here measured a nutrient.
At-risk subgroups: Older, bed-bound or constipated patients in the one ulcer case [16]; high-dose users.

Regulatory status

OTC labels: do not use for longer than 1 week; stop use and ask a doctor for rectal bleeding [1][2][3]. The kit label reports ischemic colitis in patients using the kit and the bisacodyl delayed-release tablet [4].

Population evidence

Review level, primary papers not opened: Whorwell 2024 summarizes Saunders 1977 (light and electron microscopy of rat and human intestine, focal alterations in surface absorptive cells), Saunders 1990 (single rectal biopsies after a 10 mg bisacodyl enema, transient superficial epithelial injury within 30 minutes and mild inflammation persisting up to 30 hours), Stoll 2006 (no mutagenic potential) and Borrelli 2001, concluding changes were reversible and at supratherapeutic doses, with no prospective controlled human evidence of sustained neural or smooth-muscle damage at therapeutic use [11][12]. Borrelli 2001, opened at abstract level: rats given bisacodyl 4.3 or 43 mg/kg alone for 13 weeks developed no aberrant crypt foci or tumors, while 43 mg/kg with azoxymethane increased tumors and crypts per focus [13]. Case report, Cho 2017: an 80-year-old woman with Parkinson's disease took oral bisacodyl 5 mg/day at bedtime for 6 days and developed multiple 4 to 5 cm rectal ulcers with neutrophil and lymphocyte infiltrates; healed on follow-up [16].

Mechanism

Secretory: prostaglandin-mediated chloride secretion and macrophage PGE2 with lower aquaporin-3 [9][10]. A path from this to mucosal injury is proposed in the reviews but not demonstrated in the retrieved text.

Counter-evidence held on record

Counter-evidence on record This is a drug effect on tissue under Hard Rule 2 and is not a nutrient entry. Saunders 1977 and 1990 were seen only through a review, and Saunders 1977 had no abstract in its OpenAlex record. Framing caution This is a reversible tissue effect reported on endoscopy or biopsy. It carries no supplement or nutrient implication, and this dossier makes no cancer-risk claim.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden: cell-line signals with direction inhibitory; no human or colonic-tissue data

Yellow — Low

Evidence in: Tier B

In cultured cells, the active diphenol inhibited respiration with a rise in lactate, and bisacodyl produced mitochondrial dysfunction with ATP depletion in TRPM4-expressing cancer lines. No study of mitochondria in colonic epithelium or in people taking bisacodyl was retrieved.

Full detail and limits

Limits on what this shows

Key null findings: Zeniou 2015 found no viability loss in fetal neural stem cells or HEK 293 cells and no mitochondrial measurement was reported in the retrieved text [24]. LoMascolo 2022 tested bisacodyl and BHPM in seven cell types with a Huh7 CC50 of 475 uM for bisacodyl and 465 uM for BHPM and reported no mitochondrial work [27]. No human study and no colonocyte study of bisacodyl and mitochondria was retrieved. A PubMed listing 'bisacodyl AND (oxidative stress OR mitochondrial)' returned four records, of which only the two TRPM4 papers concerned bisacodyl mechanisms [33].
At-risk subgroups: None identified.

Regulatory status

No mitochondrial statement on any label retrieved [1][2][3][4].

Population evidence

Tier B, bisacodyl or its active diphenol itself, in vitro. Nishikawa 1981, cultured Chang cells: the compound identified in the abstract as 4,4'-dihydroxy-diphenyl-(2-pyridyl)-methane (the structure of the deacetylated active metabolite; the abstract spells the name 'bis-acodyl') decreased growth at 25 to 50 ug/mL, raised lactate, and the diphenolic laxatives 'seem to increase anaerobic glycolysis by inhibition of respiration', with potassium cyanide used in confirming the respiratory effect (abstract via OpenAlex) [23]. Mizunuma 2024: bisacodyl and oxyphenisatin acetate caused oncosis (cell swelling, membrane damage, then mitochondrial dysfunction with ATP depletion) in triple-negative breast cancer lines through TRPM4; lines lacking TRPM4 were resistant (abstract via OpenAlex) [25]. Reinhold 2025: bisacodyl caused complete regression in distinct patient-derived xenografts and the abstract describes mechanisms affecting mitochondrial function; dose and exposure not retrieved [26]. Magnitude context, computed here with a molecular weight near 277: 25 to 50 ug/mL is about 90 to 180 uM, and the plasma total BHPM geometric-mean Cmax of 61 to 65 ng/mL [7] is about 0.2 uM, mostly as glucuronide. Luminal and colon-wall concentrations were not found.

Mechanism

Named in the studies: inhibition of cellular respiration [23] and poisoning of the TRPM4 ion channel leading to oncosis [25]. Whether TRPM4 or respiratory inhibition matters in normal colonic epithelium was not retrieved.

Counter-evidence held on record

Counter-evidence on record Cancer cell lines, transformed Chang cells and xenograft mice at unknown exposure do not model oral dosing in people, and the concentrations tested far exceed measured plasma BHPM. Same underlying sources support ATP production and Oxygen delivery/utilization (see Overlap map): do not count as separate confirmation. Framing caution This is a laboratory toxicology signal, not a nutrient deficiency and not a claim that labeled bisacodyl damages mitochondria in people. It supports no supplement recommendation.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress

Not graded — disclosed evidence gap

Evidence: evidence gap

No retrieved evidence on oxidative stress markers, reactive oxygen species or antioxidant enzymes with bisacodyl in people, animals or cells. This is a disclosed gap.

Full detail, limits and 1 references

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded, evidence gap

Limits on what this shows

Why no grade: Dual condition in Step 7 met: no Tier B or Tier C evidence was found to support even a yellow grade, and no circulating claim about bisacodyl and oxidative stress or antioxidants was located in the three consumer documents audited [29][30][31]. This is a disclosed evidence gap, not a finding of safety. Status after repair pass: genuine gap in PubMed titles and abstracts (three oxidative-stress phrasings returned zero records), with a residual tooling limit: full texts of the two TRPM4 cell-line papers [25][26] were not opened and could contain a ROS experiment, and the web-search budget was exhausted so no further variants (malondialdehyde, superoxide dismutase, colon cells) could be run. Re-check the full texts first on revision.

Regulatory status

The three OTC labels retrieved (10 mg suppository x2, 5 mg enteric-coated tablet) and the bowel-preparation kit label carry no statement on this category [1][2][3][4].

Evidence reviewed

A PubMed listing 'bisacodyl AND (oxidative stress OR mitochondrial)' returned 4 records: two on TRPM4 and bisacodyl in breast cancer (abstracts mention mitochondrial dysfunction, no reactive oxygen species or antioxidant markers), and two unrelated bioinformatics papers on gastric cancer and inflammatory bowel disease mitochondria. The Zeniou glioblastoma paper text had no mention of oxidative stress or reactive oxygen species, and the LoMascolo antiviral paper did not discuss it. A 2023 paper on an antioxidant laxative-support product (Marañon) did not include bisacodyl as a group or comparator. Lipid peroxidation, glutathione and antioxidant enzymes were not reported for bisacodyl in any retrieved abstract. Repair pass 2026-10-04 [35]: PubMed listings for bisacodyl with 'oxidative stress' (quoted phrase), 'reactive oxygen' and 'lipid peroxidation' each returned zero records; bisacodyl with 'free radical' and 'glutathione' were rate-limited; bisacodyl with 'antioxidant' returned 18 records, screened by title, all bowel-preparation trials of PEG plus ascorbic acid (the antioxidant is the ascorbic acid ingredient of the comparator solution, not a measured redox outcome for bisacodyl), laxative-abuse stone case reports, one NO-and-intestinal-transport review (PMID 9724140, OpenAlex record has no abstract and no bisacodyl or oxidative-stress terms) and a Senna macranthera paper; none measured a redox marker with bisacodyl. The abstracts of the two TRPM4 papers [25][26] were re-read in full from OpenAlex: they report mitochondrial dysfunction, ATP depletion and an effect on mitochondrial function, and do not state reactive oxygen species or antioxidant measurements; their full texts were not reachable (PMC reCAPTCHA, AACR 403), so a ROS experiment inside the full text cannot be excluded.

Mechanism

None identified in any retrieved source.

Channels tried

Web search: 'bisacodyl colonic epithelial damage mitochondria oxidative stress rat' (results unrelated to bisacodyl), 'bisacodyl cytotoxic mitochondrial membrane potential ROS cells in vitro drug repurposing' (surfaced the glioblastoma and Chikungunya papers, opened), 'bisacodyl oxidative stress malondialdehyde superoxide dismutase colon rats laxative' (results unrelated or on colonic transport, one antioxidant product paper opened); three further queries (oxidative phosphorylation or complex I, DDPM mechanism follow-up, reactive oxygen species in colon or Caco-2 cells) were refused by the exhausted budget; PubMed listing as above; PubMed listing 'bisacodyl mitochondria' returned 429 and was not refetched. Repair pass: PubMed listings 'bisacodyl "oxidative stress"' (0 records), 'bisacodyl "reactive oxygen"' (0), 'bisacodyl "lipid peroxidation"' (0), 'bisacodyl antioxidant' (18, screened), '"bowel preparation" "oxidative stress"' (404, which a paired non-format query showed means zero records), 'bisacodyl oxidative' and 'bisacodyl glutathione' and 'bisacodyl "free radical"' (429, not refetched); OpenAlex single-record lookups for PMIDs 39041239, 39932272 and 9724140 (answered); PMC11322923 (reCAPTCHA) and the AACR PDF for the Reinhold paper (403); OpenAlex works-search (429); web search returned only generic reactive-oxygen-species reviews for one bisacodyl query and then the session budget (200 of 200) refused further queries. Network state this review: per the review brief, direct HTTP to PubMed, eutils, Crossref, Europe PMC, OpenAlex, Semantic Scholar, Unpaywall, DailyMed and accessdata.fda.gov is blocked by organization network policy (403 on CONNECT) and was neither attempted nor routed around. Through the fetch tool: PubMed search-listing pages answered for some queries and returned 429 (with an instruction not to refetch) for others, which were not refetched; PubMed single-article pages returned 429 or a bot check; PubMed Central returned a reCAPTCHA page; Wiley, Clinical Gastroenterology and Hepatology and AACR pages returned 403; OpenAlex single-record lookups (by PMID or DOI) answered except two that returned 429; OpenAlex works-search returned 429; the openFDA label API was used for labels; the web-search tool answered 16 queries and then reported its session budget exhausted (200 of 200), so three further planned queries were not run. No email address or other identifying information was sent to any service. See the access note under Sources.

Counter-evidence held on record

Counter-evidence and null findings No study measuring this category with bisacodyl in the cohort was retrieved, so there is no null result to quote. Framing caution Do not read this entry as reassurance. It records that retrieval found nothing usable, with the tooling limits listed above and in Sources.

[35] PubMed search-listing pages queried in the repair pass, 2026-10-04 — Zero records (PubMed message 'No results were found'; a 404 on the format=pubmed form was shown to mean zero records): bisacodyl copper; bisacodyl ceruloplasmin; bisacodyl ferritin; bisacodyl "serum iron"; bisacodyl "oxidative stress"; bisacodyl "reactive oxygen"; bisacodyl "lipid peroxidation"; bisacodyl "trace elements" (404); "bowel preparation" "oxidative stress" (404). Records returned and screened by title: bisacodyl hemoglobin (2); bisacodyl anemia (4); bisacodyl iron (1, PMID 22422379); bisacodyl antioxidant (18, ascorbic-acid bowel-preparation trials and laxative-abuse case reports); bisacodyl AND (oxidative stress OR ROS OR malondialdehyde OR glutathione) (1, an unrelated malaria paper that lists bisacodyl only as a registry substance). Rate-limited (429), not read: bisacodyl AND (copper OR ceruloplasmin); bisacodyl AND (ferritin OR serum iron OR iron absorption); bisacodyl oxidative; bisacodyl glutathione; bisacodyl zinc; bisacodyl "iron deficiency"; bisacodyl "free radical"; bisacodyl mitochondria. OpenAlex records for PMID 39041239 and PMID 39932272 re-read for abstract text; PMID 9724140 record had no abstract. Full texts of the TRPM4 papers not reachable (PMC reCAPTCHA; AACR PDF 403).Listings screened by title only; no record from these listings is used for any grade.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

Evidence: evidence gap

No retrieved evidence on copper absorption, status or ceruloplasmin with bisacodyl in people or animals. This is a disclosed gap.

Full detail and limits

Limits on what this shows

Why no grade: Dual condition in Step 7 met on what was reachable: no Tier B or Tier C copper evidence for bisacodyl was found, and no circulating copper claim for bisacodyl was located to rebut as white. This is a disclosed evidence gap, not a finding of safety. Status after repair pass: genuine gap on PubMed, where three copper-specific queries (copper, ceruloplasmin, trace elements) each returned zero records; the only residual tooling limit is the unread 'bisacodyl zinc' and combined OR listings. Kept separate from Iron.

Regulatory status

The three OTC labels retrieved (10 mg suppository x2, 5 mg enteric-coated tablet) and the bowel-preparation kit label carry no statement on this category [1][2][3][4].

Evidence reviewed

The two PubMed listings attempted for copper did not return a usable list: 'bisacodyl AND (copper OR ceruloplasmin)' returned 429 and was not refetched, and 'bisacodyl copper' returned a 404 error page that may mean zero matching records but could not be confirmed. The three consumer documents audited name only calcium and potassium for bisacodyl laxatives [29][30][31]. Copper content of tablets or suppositories is not stated on the labels retrieved. Repair pass 2026-10-04 [35]: the earlier 404 for 'bisacodyl copper' was resolved. The same query without the format parameter shows the PubMed message 'No results were found', so the 404 means zero matching records. 'bisacodyl ceruloplasmin' also returned zero records, and 'bisacodyl "trace elements"' returned a 404 (zero records by the same behavior). The combined 'bisacodyl AND (copper OR ceruloplasmin)' listing returned 429 again and was not refetched; 'bisacodyl zinc' was rate-limited and not read. A single web search for bisacodyl with serum copper and zinc returned only unrelated trace-element papers (critically ill patients, leukemia, psoriasis, zinc-induced copper deficiency), none about bisacodyl.

Mechanism

None identified in any retrieved source.

Channels tried

PubMed listings 'bisacodyl AND (copper OR ceruloplasmin)' (429) and 'bisacodyl copper' (404); consumer documents [29][30][31] read for any copper claim (none); no web-search query specific to copper was run before the budget ended. Repair pass: PubMed 'bisacodyl copper' (zero records, confirmed against the non-format page), 'bisacodyl ceruloplasmin' (zero), 'bisacodyl "trace elements"' (404, zero), 'bisacodyl AND (copper OR ceruloplasmin)' (429), 'bisacodyl zinc' (429, twice with different URL forms); one web search 'bisacodyl serum copper zinc trace elements' (no bisacodyl result). Network state this review: per the review brief, direct HTTP to PubMed, eutils, Crossref, Europe PMC, OpenAlex, Semantic Scholar, Unpaywall, DailyMed and accessdata.fda.gov is blocked by organization network policy (403 on CONNECT) and was neither attempted nor routed around. Through the fetch tool: PubMed search-listing pages answered for some queries and returned 429 (with an instruction not to refetch) for others, which were not refetched; PubMed single-article pages returned 429 or a bot check; PubMed Central returned a reCAPTCHA page; Wiley, Clinical Gastroenterology and Hepatology and AACR pages returned 403; OpenAlex single-record lookups (by PMID or DOI) answered except two that returned 429; OpenAlex works-search returned 429; the openFDA label API was used for labels; the web-search tool answered 16 queries and then reported its session budget exhausted (200 of 200), so three further planned queries were not run. No email address or other identifying information was sent to any service. See the access note under Sources.

Counter-evidence held on record

Iron

Not graded — disclosed evidence gap

Evidence: evidence gap

No retrieved evidence on iron absorption, ferritin, transferrin saturation or iron-deficiency anemia with bisacodyl. This is a disclosed gap.

Full detail, limits and 1 references

Limits on what this shows

Why no grade: Dual condition in Step 7 met: no Tier B or Tier C iron evidence for bisacodyl was found, and no circulating iron claim for bisacodyl appeared in the three consumer documents audited [29][30][31] (the Riordan, InVite chart and InVite podcast entries list calcium and potassium only). This is a disclosed evidence gap, not a finding of safety. Status after repair pass: genuine gap on the PubMed channel, where six iron-related phrasings (iron, ferritin, serum iron, hemoglobin, anemia, and the original combined listing) returned either zero records or records with no iron measurement for bisacodyl; the 'iron deficiency' variant was rate-limited. Kept separate from Copper and from Oxygen delivery/utilization.

Regulatory status

The three OTC labels retrieved (10 mg suppository x2, 5 mg enteric-coated tablet) and the bowel-preparation kit label carry no statement on this category [1][2][3][4].

Evidence reviewed

PubMed listing 'bisacodyl AND (iron OR ferritin OR hemoglobin OR anemia)' returned 6 records: a sodium picosulfate/magnesium citrate colorectal cleanser review (Drugs 2009), an orthogeriatric prescribing-pattern paper (2026), a lead-shot ingestion case, a colon-capsule castor-oil booster paper, a CT colonography minimal-preparation paper, and a sennoside-B/picosulfate colonoscopy preparation comparison. None measured iron status or hemoglobin in bisacodyl users; the sodium picosulfate and senna papers are other agents. A web search for 'bisacodyl hemoglobin OR anemia OR iron deficiency laxative' returned only iron-deficiency papers on acid-modifying medicines, magnesium overuse and iron supplements, none about bisacodyl. The only iron or hemoglobin number found was a single rectal-ulcer patient's hemoglobin of 12.2 and 12.9 g/dL [16], which is not an iron measure. Rectal bleeding as a label stop-use sign is a bleeding warning and not an iron finding. Repair pass 2026-10-04 [35]: PubMed 'bisacodyl ferritin' and 'bisacodyl "serum iron"' returned zero records. 'bisacodyl hemoglobin' returned 2 records (a sodium picosulfate/magnesium citrate review and a lead-shot ingestion case). 'bisacodyl anemia' returned 4 records (CT colonography minimal-preparation regimes, colon capsule castor-oil booster, an orthogeriatric prescribing paper, a saccharosum-sennoside B versus sodium picosulfate colonoscopy comparison). 'bisacodyl iron' returned 1 record, the 2012 CT colonography minimal-preparation paper (PMID 22422379), whose MeSH terms include iron-deficiency anemia: this is the indication for the examination in the studied patients, not a measured effect of bisacodyl on iron status, so it is confounding by indication and not usable as evidence (Hard Rule 6). Its abstract was not opened. No bowel-preparation trial with a bisacodyl arm and a ferritin, serum iron or hemoglobin outcome was found.

Mechanism

None identified in any retrieved source.

Channels tried

PubMed listing 'bisacodyl AND (iron OR ferritin OR hemoglobin OR anemia)' (6 records, none usable); web search 'bisacodyl hemoglobin OR anemia OR iron deficiency laxative association study' (no bisacodyl-specific result); consumer documents [29][30][31] read (no iron claim). Repair pass: PubMed 'bisacodyl ferritin' (zero), 'bisacodyl "serum iron"' (zero), 'bisacodyl hemoglobin' (2 records), 'bisacodyl anemia' (4), 'bisacodyl iron' (1), 'bisacodyl "iron deficiency"' (429); web search 'bisacodyl bowel preparation serum iron ferritin hemoglobin colonoscopy' (patient instruction leaflets only, no study). Network state this review: per the review brief, direct HTTP to PubMed, eutils, Crossref, Europe PMC, OpenAlex, Semantic Scholar, Unpaywall, DailyMed and accessdata.fda.gov is blocked by organization network policy (403 on CONNECT) and was neither attempted nor routed around. Through the fetch tool: PubMed search-listing pages answered for some queries and returned 429 (with an instruction not to refetch) for others, which were not refetched; PubMed single-article pages returned 429 or a bot check; PubMed Central returned a reCAPTCHA page; Wiley, Clinical Gastroenterology and Hepatology and AACR pages returned 403; OpenAlex single-record lookups (by PMID or DOI) answered except two that returned 429; OpenAlex works-search returned 429; the openFDA label API was used for labels; the web-search tool answered 16 queries and then reported its session budget exhausted (200 of 200), so three further planned queries were not run. No email address or other identifying information was sent to any service. See the access note under Sources.

Counter-evidence held on record

[35] PubMed search-listing pages queried in the repair pass, 2026-10-04 — Zero records (PubMed message 'No results were found'; a 404 on the format=pubmed form was shown to mean zero records): bisacodyl copper; bisacodyl ceruloplasmin; bisacodyl ferritin; bisacodyl "serum iron"; bisacodyl "oxidative stress"; bisacodyl "reactive oxygen"; bisacodyl "lipid peroxidation"; bisacodyl "trace elements" (404); "bowel preparation" "oxidative stress" (404). Records returned and screened by title: bisacodyl hemoglobin (2); bisacodyl anemia (4); bisacodyl iron (1, PMID 22422379); bisacodyl antioxidant (18, ascorbic-acid bowel-preparation trials and laxative-abuse case reports); bisacodyl AND (oxidative stress OR ROS OR malondialdehyde OR glutathione) (1, an unrelated malaria paper that lists bisacodyl only as a registry substance). Rate-limited (429), not read: bisacodyl AND (copper OR ceruloplasmin); bisacodyl AND (ferritin OR serum iron OR iron absorption); bisacodyl oxidative; bisacodyl glutathione; bisacodyl zinc; bisacodyl "iron deficiency"; bisacodyl "free radical"; bisacodyl mitochondria. OpenAlex records for PMID 39041239 and PMID 39932272 re-read for abstract text; PMID 9724140 record had no abstract. Full texts of the TRPM4 papers not reachable (PMC reCAPTCHA; AACR PDF 403).Listings screened by title only; no record from these listings is used for any grade.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk: neutral to reverse direction; one small uncontrolled human study and a bioreactor model

Yellow — Low

Evidence in: Tier B

In 12 constipated patients treated with bisacodyl, fecal flora reportedly moved toward normal, and in a computer-controlled colon model bisacodyl produced no significant composition change against control. No study reported harmful dysbiosis from bisacodyl.

Full detail and limits

Limits on what this shows

Key null findings: The bioreactor study is itself a near-null on composition [22]. Two bowel-preparation microbiome studies were opened and excluded because bisacodyl was not in the cohort: Ghouri 2025 (PEG 3350 only) and Nagata 2019 (sodium picosulfate, sennoside and magnesium citrate) [32]. No bisacodyl-only fecal sequencing study in healthy people was retrieved. Whorwell 2024 identified no bisacodyl-specific microbiome study [11].
At-risk subgroups: None identified.

Regulatory status

No microbiome statement on any label retrieved [1][2][3][4].

Population evidence

Tier B, bisacodyl in the cohort. Khalif 2005, Dig Liver Dis: 57 patients with functional constipation; Bifidobacterium and Lactobacillus were significantly lower and potentially pathogenic bacteria or fungi increased in the constipated patients; the 12 with severely delayed transit were retested after bisacodyl, and flora, serum ovalbumin (a permeability marker) and several immune parameters moved toward normal. Uncontrolled before-and-after design; abstract-level read through a summarizing fetch tool [21]. A manufacturer-hosted review quotes the same result as four weeks of bisacodyl giving a decrease in potentially pathogenic organisms and an increase in Bifidobacterium and Bacteroides, citing Khalif 2005 [8]. Bothe 2021, TIM-2 in vitro model of the proximal colon with human microbiota, bisacodyl 5 mg/day: no significant composition change versus control, slight Bifidobacterium decrease, total SCFA 351 +/- 17 vs control 332 +/- 34 (units as printed by the summarizing tool), ammonia highest of the three laxatives, conclusion that lactulose but not macrogol or bisacodyl is prebiotic [22].

Mechanism

Not characterized. Bisacodyl is activated by colonic bacteria [4], so the flora handle the drug; no route from composition to a nutrient outcome is shown.

Counter-evidence held on record

Counter-evidence on record Constipation itself alters flora and is presumed to confound any comparison (Hard Rule 6); the human result is uncontrolled and may reflect relief of constipation and not a drug effect on bacteria. The summary in [8] is manufacturer-hosted. Framing caution This is a composition signal in constipated patients and a model, not a nutrient deficiency and not evidence of dysbiosis from bisacodyl. It does not support probiotic or supplement recommendations.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

ATP production: ATP lowered in cell lines; no human data

Yellow — Low

Evidence in: Tier B

Bisacodyl lowered ATP sharply in quiescent glioblastoma stem-like cells and, per the oncosis paper, depleted ATP in TRPM4-expressing breast cancer lines. ATP was the assay readout in the first study, so part of the signal reflects cell death.

Full detail and limits

Limits on what this shows

Key null findings: No ATP or energy-charge measurement in colonic tissue, in healthy animals or in people was retrieved. Normal fetal neural stem cells and HEK 293 cells were unaffected in viability [24].
At-risk subgroups: None identified.

Regulatory status

No ATP or energy statement on any label retrieved [1][2][3][4].

Population evidence

Tier B, bisacodyl itself. Zeniou 2015 (PLOS ONE): screen of 1,120 compounds using ATP-based viability; bisacodyl reduced ATP to about 5% of control in quiescent glioblastoma stem-like cells with EC50 about 1 uM (reported 1.07 for TG1, 1.3 for TG16, 0.5 uM for OB1) and above 10 uM in proliferating cells; trypan blue and 7-AAD staining showed that the ATP fall in quiescent TG1 cells came with cell death; in primary human astrocytes bisacodyl lowered ATP without reducing viability (tested at 50 uM); in culture bisacodyl converted to its deacetylated form with half-lives of about 4 and 2 hours. The fetch tool printed the year as 2014; the year was not independently confirmed [24]. Mizunuma 2024: ATP depletion within oncosis in TRPM4-expressing lines [25]. Nishikawa 1981: raised lactate with inhibited respiration, a pattern consistent with compensatory glycolysis, no ATP value reported in the abstract [23].

Mechanism

Not investigated in Zeniou (the authors state the molecular target was under investigation) [24]; TRPM4 poisoning and respiratory inhibition in [25][23].

Counter-evidence held on record

Counter-evidence on record Shares its sources with Mitochondrial burden and Oxygen delivery/utilization (Overlap map). The astrocyte result shows ATP can fall without death, which is a metabolic effect of unknown reversibility. Exposure well above plasma BHPM. Framing caution This is not an energy-depletion or fatigue claim for people and gives no basis for energy supplements.

Oxygen delivery/utilization: cellular respiration inhibition in one 1981 cell study; no hemoglobin or delivery data

Yellow — Low

Evidence in: Tier B (utilization side only)

The only retrieved signal is cell-level: inhibition of respiration by the active diphenol in cultured cells. Nothing was retrieved on hemoglobin, hematocrit, red-cell mass, arterial oxygenation or methemoglobin with bisacodyl.

Full detail and limits

Limits on what this shows

Key null findings: No hemoglobin outcome from a bisacodyl cohort was retrieved. The drug's intended stimulant action is not an oxygen-delivery effect and is not graded here (Hard Rule 2). Kept separate from ATP production (Hard Rule 7) even though the utilization signal shares a source.
At-risk subgroups: None identified.

Regulatory status

No oxygen or anemia statement on any label. Both suppository labels and the tablet label say to stop use for rectal bleeding [1][2][3], a bleeding sign and not an oxygen-delivery measurement.

Population evidence

Utilization, Tier B: Nishikawa 1981, cultured Chang cells, respiratory inhibition with raised lactate and anaerobic glycolysis, cyanide as comparator [23]. Delivery side, nothing usable: a single bisacodyl-induced rectal ulcer case in an 80-year-old woman with Parkinson's disease reported hemoglobin 12.2 g/dL and then 12.9 g/dL, a one-patient measurement and not an anemia finding [16]. A PubMed listing 'bisacodyl AND (methemoglobin OR hemolysis OR oxygen)' returned one record, the Chang-cell paper [33]; the iron and anemia listing returned six records, none about hemoglobin in bisacodyl users (see the Iron entry).

Mechanism

Cell-level respiratory inhibition as in Mitochondrial burden [23]. No mechanism linking bisacodyl to red-cell mass or hemoglobin oxygen carriage is described in any retrieved source.

Counter-evidence held on record

Counter-evidence on record The utilization grade rests entirely on one 1981 abstract-level cell study that also supports Mitochondrial burden and ATP production (Overlap map). The delivery half of this category is a gap, disclosed in the Iron entry and here. Framing caution This is not an anemia or oxygen-carrying claim. No hemoglobin effect of bisacodyl is established or excluded by this entry.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

Calcium and potassium "depleted" by bisacodyl laxatives, stated without dose or duration
Where it comes from: InVite Health depletion chart and podcast (Dulcolax, Correctol, Feen-a-Mint, Carter's Little Pills, PMS-Bisacodyl: "Calcium, Potassium") and the Riordan Clinic handout ("Laxatives with Bisacodyl ... Calcium, Potassium"); no citations in any of the three [29][30][31].
Why it fails: All three are Tier D and appear to repeat one claim. Stated without dose or duration the claim is not supported: the labels limit use to 1 week [1][3], no controlled study showed a potassium or calcium change at labeled use, and the one bisacodyl-arm trial found no potassium difference [20]. Overuse-qualified versions with case-level support are graded yellow in this dossier (potassium, calcium, fluid and sodium). Published only as a rebuttal of the unqualified wording.
Unspecified "loss of essential nutritional factors"
Where it comes from: Chronic-use caution in the Drugs.com monograph for bisacodyl, which pairs persistent diarrhea, hypokalemia and dehydration with this phrase [6].
Why it fails: It names no nutrient and no measured marker, so it cannot be falsified (Hard Rule 3). The named parts of the sentence (hypokalemia, dehydration, protein loss) are graded separately. Published only as a rebuttal of the unnamed remainder.
"No systemic absorption, so no systemic effects" (reverse reassurance claim)
Where it comes from: Manufacturer-hosted review: "The active metabolite does not undergo systemic absorption" [8].
Why it fails: Contradicted by the drug's own data: total BHPM was measured in plasma (geometric-mean Cmax 61 to 65 ng/mL on 10 mg daily) and about 12% of the dose appeared in urine as BHPM [7]. This does not show a nutrient effect; it shows that exposure is not zero. Filed here because the reader may meet the claim as a reason to skip all review.

How the body handles this medication

Activation and absorption: Prodrug converted to BHPM by intestinal brush-border enzymes and colonic bacteria; the kit label says oral tablet pharmacokinetics have not been adequately characterized. The healthy-volunteer paper states that neither bisacodyl nor sodium picosulfate is absorbed from the gut to a significant degree and that conversion is by deacetylases on the small-intestinal and colonic mucosa. Onset: oral 6 to 12 hours; rectal about 15 minutes to 1 hour. WHO DDD 10 mg oral and 10 mg rectal.[4] kit label; [7] Friedrich 2011; [1][2][3] OTC labels; [5] WHO ATC/DDD Index
Systemic exposure: In 8 lactating women given bisacodyl 10 mg daily, total BHPM (free plus glucuronides) peaked at about 4 to 5 hours: single-dose Cmax 20.5 to 195 ng/mL (geometric mean 64.6), steady-state Cmax 19.7 to 118 (geometric mean 60.7). Free BHPM in plasma was minimal. About 12% of the bisacodyl dose was excreted as BHPM in urine at steady state. BHPM stayed below 1 ng/mL in breast milk. A manufacturer-hosted review states that the active metabolite does not undergo systemic absorption, which conflicts with the measured plasma and urine values and is not resolved here.[7] Friedrich 2011 (abstract-level read via summarizing tool); [8] Landes 2021
Metabolism and CYP450: Any absorbed bisacodyl is metabolized in the liver and excreted in urine per the monograph; BHPM circulates mainly as glucuronides. No CYP450 substrate, inducer or inhibitor data were retrieved and no label has a pharmacokinetic section for the OTC products: unknown, not absent.[6] Drugs.com monograph; [7]; [1][2][3]
Elimination and accumulation: Urinary BHPM as above. In patient-derived xenograft mice, bisacodyl had a 5.8-hour terminal half-life and penetrated tumor and brain (mouse abstract; dose not retrieved). Accumulation in renal or hepatic impairment is not stated in any retrieved human source.[7]; [26] Reinhold 2025 abstract
Mechanism and electrolyte handling: Secretagogue and prokinetic. Desacetyl bisacodyl induced chloride secretion in rat mid and rectal colon, not proximal colon, through a prostaglandin-dependent route; in rats, bisacodyl raised colonic macrophage PGE2 and lowered aquaporin-3 (about 40% lower in HT-29 cells). WHO describes the A06AB group as agents that mainly inhibit absorption of electrolytes and water. A manufacturer-hosted figure caption describes potassium secretion when BHPM acts on the mucosa from the lumen. No renal tubular effect is described.[9] Fujita 2016; [10] Ikarashi 2011; [5]; [8]
Interactions: Labels: do not take within 1 hour of an antacid or milk (enteric coating). The monograph adds H2 blockers and proton pump inhibitors to the coating-erosion list and notes faster transit may reduce absorption of co-administered oral drugs. The kit label says oral medicines taken within 1 hour of starting the PEG solution may not be absorbed fully. These are formulation and transit timing interactions (Hard Rule 4), not nutrient depletion; no food, mineral or antacid interaction with a nutrient outcome was found.[3] 5 mg tablet label; [4] kit label; [6] monograph

What the research says is worth watching

General information from the medication label and the studies above. It is not personal medical advice, and any change belongs with your prescriber.

Monitoring
Labs, only if indicated
When use is prolonged, high-dose or concealed and comes with persistent diarrhea, muscle weakness, palpitations, swelling or a low urine volume, a basic chemistry panel is reasonable: potassium, sodium, bicarbonate, calcium and albumin [6][14][17][18]. No routine screening for occasional labeled use is supported by the evidence retrieved. This is a monitoring prompt, not a deficiency claim.
Monitoring
Interaction timing
Labels: do not take the oral tablet within 1 hour after an antacid or milk [3][4]; the monograph adds H2 blockers and proton pump inhibitors for coating erosion [6]. Because bisacodyl speeds transit, a pharmacist review is sensible for narrow-therapeutic-index oral medicines, and the kit label says oral medicines taken within 1 hour of the solution may not be absorbed fully [4]. No nutrient separation interval is stated in any retrieved source, so none is given.
Monitoring
Duration and warning signs
Labels limit self-treatment to 1 week and say to stop and ask a doctor for rectal bleeding or no bowel movement after use [1][3]. A sudden change in bowel habits lasting more than 2 weeks is a label reason to ask a doctor first [1][3].
Monitoring
At-risk groups
Concealed or long-term high-dose users; people with eating disorders who use laxatives [18]; older or bed-bound people (rectal ulcer case [16]); pregnancy and breast-feeding (BHPM below 1 ng/mL in milk in 8 bisacodyl users [7]; no other pregnancy data retrieved); children (the Walgreens suppository label gives half a suppository for ages 6 to 11 and says do not use under 6 [1]). Renal and hepatic impairment accumulation: no data retrieved.
Monitoring
Confounders to keep in view
Constipation itself, poor intake, opioids, other laxatives, diuretics, vomiting and eating-pattern changes. Hard Rule 6 presumes confounding by indication, so low levels in a bisacodyl user are not attributed to the drug without further evidence.
Monitoring
Supplements
No supplement dose appears anywhere in this dossier, so no upper-intake-level comparison applies. Nothing here supports adding potassium, calcium, protein, iron, copper, probiotics or antioxidants because of bisacodyl. The 300 to 500 mg/day and mg/kg figures are misuse or animal exposures in cited studies and not recommendations.

Overlap map, to prevent double counting

Mitochondrial burden
Shares evidence with: ATP production; Oxygen delivery/utilization
Note: All three rest on the same small set of in vitro bisacodyl papers: Nishikawa 1981 [23], Zeniou 2015 [24], Mizunuma 2024 [25] and Reinhold 2025 [26]. Treat as one cell-line line of evidence across three entries, not three confirmations.
Oxygen delivery/utilization
Shares evidence with: Mitochondrial burden; ATP production; Iron (ungraded)
Note: The grade rests only on cellular respiration inhibition in [23]. The delivery half (hemoglobin, red-cell mass) has no source of its own and shares only the empty PubMed iron listing with Iron.
Potassium
Shares evidence with: Fluid, sodium and acid-base; Calcium; Plasma protein loss
Note: The misuse case literature [17][18][19] and the monograph [6] support potassium, fluid and calcium at once. Sidler 2019 [17] involves three laxative agents. Treat as one weak case-level line, not three or four. The kit label [4] covers the PEG kit as a whole.
Plasma protein loss
Shares evidence with: Potassium; Colonic mucosal injury
Note: Heizer 1968 [14] stands alone for protein loss; the monograph sentence [6] is shared with the potassium and fluid entries and is reference text without a visible primary source.
Calcium
Shares evidence with: Fails verification: calcium and potassium claim
Note: The consumer sources [29][30][31] are the origin of the calcium claim and are one repeated Tier D statement; the monograph and kit label are the only Tier B support.
Gut microbiome risk
Shares evidence with: Colonic mucosal injury
Note: Both depend on bisacodyl activation by colonic flora and mucosal enzymes [4][7]; different outcomes and different studies, so mechanistic overlap only.
Colonic mucosal injury
Shares evidence with: Potassium; Fluid, sodium and acid-base
Note: The secretory mechanism papers [9][10] explain both the stool-water loss and the mucosal effect; they are not outcome evidence for either.
Oxidative stress; Copper; Iron
Shares evidence with: Each other
Note: Independent entries that share only the same PubMed channels and the same absence of retrieved evidence. No shared source supports any of them.

All references used above

Bisacodyl

Findings for this medication

What the research found

Potassium: loss with chronic or high-dose misuse, case level only; direction depletion by fecal loss

Plasma protein loss into the gut: one bisacodyl case from 1968; outcome of misuse, not dietary protein

Fluid, sodium and acid-base disturbance with misuse (context flag)

Calcium: reference-text caution and circulating claim, no measurement isolating bisacodyl

Colonic mucosal injury: drug tissue effect, not a nutrient

The five body-system areas

⚡Mitochondrial Burden

Mitochondrial burden: cell-line signals with direction inhibitory; no human or colonic-tissue data

💥Oxidative Stress

Oxidative stress

⚖️Copper and Iron Balance

Copper

Iron

🌿Gut Microbiome Risk

Gut microbiome risk: neutral to reverse direction; one small uncontrolled human study and a bioreactor model

💨Oxygen and ATP Output

ATP production: ATP lowered in cell lines; no human data

Oxygen delivery/utilization: cellular respiration inhibition in one 1981 cell study; no hemoglobin or delivery data

Claims checked and not supported

Calcium and potassium "depleted" by bisacodyl laxatives, stated without dose or duration

Unspecified "loss of essential nutritional factors"

"No systemic absorption, so no systemic effects" (reverse reassurance claim)

How the body handles this medication

What the research says is worth watching

Overlap map, to prevent double counting

Mitochondrial Burden

Oxidative Stress

Copper and Iron Balance

Gut Microbiome Risk

Oxygen and ATP Output